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Background: In 1952 Papanicolaou et al. first diagnosed and graded cervical carcinomas based on individual “abnormal
DNA contents” and cellular phenotypes. Surprisingly current papilloma virus and mutation theories of carcinomas do not
mention these individualities. The viral theory holds that randomly integrated, defective genomes of papilloma viruses,
which are often untranscribed, cause cervical carcinomas with unknown cofactors 20–50 years after infection. Virus-free
carcinomas are attributed to mutations of a few tumor-suppressor genes, especially the p53 gene. But the paradox of
how a few mutations or latent defective viral DNAs would generate carcinomas with endless individual DNA contents,
degrees of malignancies and cellular phenotypes is unsolved. Since speciation predicts individuality, we test here the
theory that cancers are autonomous species with individual clonal karyotypes and phenotypes. This theory postulates
that carcinogens induce aneuploidy. By unbalancing mitosis genes aneuploidy catalyzes chain reactions of karyotypic
evolutions. Most such evolutions end with non-viable karyotypes but a few become new cancer karyotypes. Despite
congenitally unbalanced mitosis genes cancer karyotypes are stabilized by clonal selections for cancer-specific
autonomy.
Results: To test the prediction of the speciation theory that individual carcinomas have individual clonal karyotypes and
phenotypes, we have analyzed here the phenotypes and karyotypes of nine cervical carcinomas. Seven of these
contained papilloma virus sequences and two did not. We determined phenotypic individuality and clonality based on
the morphology and sociology of carcinoma cells in vitro. Karyotypic individuality and clonality were determined by
comparing all chromosomes of 20 karyotypes of carcinomas in three-dimensional arrays. Such arrays list chromosome
numbers on the x-axis, chromosome copy numbers on the y-axis and the number of karyotypes arrayed on the z-axis.
We found (1) individual clonal karyotypes and phenotypes in all nine carcinomas, but no virus-specific markers, (2) 1-to-1
variations between carcinoma-specific karyotypes and phenotypes, e.g. drug-resistance and cell morphology, (3)
proportionality between the copy numbers of chromosomes and the copy numbers of hundreds of over- and under-
expressed mRNAs, (4) evidence that tobacco-carcinogens induce cervical carcinomas via aneuploidy, consistent with the
speciation theory.
Conclusions: Since the individual clonal karyotypes of nine carcinomas correlated and co-varied 1-to-1 with complex
individual transcriptomes and phenotypes, we have classical genetic and functional transcriptomic evidence to conclude
that these karyotypes encode carcinomas - much like the clonal karyotypes that encode conventional species. These
individual karyotypes explain the individual “DNA contents”, the endless grades of malignancies and the complex
individual transcriptomes and phenotypes of carcinomas.
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In 1952 Papanicolaou et al. first diagnosed and graded
cervical carcinomas microscopically based on individual
“abnormal DNA contents” and cellular phenotypes [1].
These individualities of cervical carcinomas have since
been confirmed and extended by numerous cytometric
and cytogenetic studies [2-21]. Based on these classic
characteristics ‘Pap-tests’ are used to this day to diag-
nose and grade carcinomas.
Surprisingly, the current papilloma virus and mutation
theories of carcinomas do not mention the individual DNA
contents and phenotypes of carcinomas. The viral theory
holds that randomly integrated defective viral genomes,
which are non-immunogenic and often untranscribed, cause
cervical carcinomas with unknown cofactors 20–50 years
after infection [13,17,18,21-36]. Since defective and inactive
papilloma viral sequences are present in at least 50 million
(30%) of cancer-free American females [37] as compared to
12,000 annual cervical carcinomas [38], these cofactors must
be very rare events. On the other hand the virus-free car-
cinomas are attributed to mutations of certain tumor-
suppressor genes, especially the p53 gene [12,13,16,39-45].
But the paradox of how either a few mutations or latent
defective viral genomes generate carcinomas with endless
“abnormal DNA contents”, grades of malignancies and
phenotypic individualities is unsolved [1].Figure 1 The speciation theory of cancer: Carcinogenesis in one stocha
or spontaneous accidents induce aneuploidy, i.e., losses or gains of chromoso
and thus mitosis genes aneuploidy initiates chain reactions of automatic kary
evolutions end with non-viable karyotypes, but a few become new cancer ka
autonomous precursors are too unstable to accumulate. Because of its conge
m2-rates, but is stabilized by clonal selection for autonomy within cancer-spe
aneuploid cells are shown as half round-half squares and cancer cells are shoSince speciation predicts individuality, we test here the the-
ory that cancers are autonomous species with new individual
karyotypes and phenotypes [46-53]. This theory postulates
that carcinogens or spontaneous events initiate speciation by
inducing aneuploidy. Aneuploidy catalyzes chain reactions of
karyotypic evolutions automatically, because it unbalances
chromosomes and thus mitosis genes [54-58]. Most such
evolutions end with non-viable karyotypes, but a few become
new cancer karyotypes at very low rates ‘one cancer-one
karyotype’ [50,57,58] (Figure 1). Despite congenitally un-
balanced mitosis genes cancer karyotypes are stabilized
[46,50,59-62], indeed immortalized [58] by clonal selec-
tions for cancer-specific autonomy (Figure 1). The resulting
karyotypic flexibility and corresponding clonal heterogen-
eity are thus proportional to the degrees of cancer-specific
aneuploidy [55,59,60,62,63] (see below).
The relevance of this theory to cervical carcinomas is
supported by: (1) A plethora of classic evidence for ab-
normal DNA contents or aneuploidies in cervical car-
cinomas [1-21,64-67], (2) Recent evidence that the copy
numbers of the mRNAs of individual carcinomas
[33,45,68-72], like those of other cancers [73-78], are
proportional to the copy numbers of the corresponding
carcinoma-specific chromosomes (See Results regarding
transcriptomes of cervical carcinomas), and (3) Induc-
tion of cervical carcinomas by aneuploidogenic cigarettestic karyotypic step. The speciation theory postulates that carcinogens
mes at dose-dependent rates, termed m1. By unbalancing chromosomes
otypic evolutions at aneuploidy-dependent rates, termed m2. Most such
ryotypes at very low rates, termed m3 – in one stochastic step, as non-
nital “aneuploidy” (relative to normal) the cancer karyotype is variable at
cific margins. Since aneuploidy changes the normal phenotype (squares),
wn as circles.
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ory [27,79-83].
In this study we have investigated the predictions of the
speciation theory that, (1) Cervical carcinomas have individ-
ual clonal karyotypes, transcriptomes and phenotypes irre-
spective of integrated viral sequences, (2) There are 1-to-1
correlations between phenotypic and karyotypic variations,
e.g. intrinsic and acquired drug-resistance and cell morph-
ology, (3) The copy numbers of hundreds of over- and
under-expressed mRNAs of carcinomas are proportional to
the copy numbers of the corresponding chromosomes of
individual carcinomas, (4) Cigarette smoke carcinogens can
initiate carcinomagenesis by inducing aneuploidy. As we
show below our investigations have indeed confirmed all of
these predictions of the speciation theory.
Results
Individual phenotypes of cervical carcinomas
The speciation theory predicts that cervical carcin-
omas have individual clonal phenotypes based on indi-
vidual clonal karyotypes (Background). To test this
prediction we analyzed the phenotypes and karyotypes
of nine individual cervical carcinomas. Relevant cyto-
genetic and phenotypic data of these nine carcinomas
are summarized in Table 1. As is shown in this table
and in the literature, two of the nine carcinomas,
namely C-4II and C-33A are near-diploid, and seven,
namely SiHa, HT-3, ME-180, MS-751, CaSki, SW-756
and HeLa are near-triploid [14,18,19,21,40,42,43,84].
Both C-33A and HT-3 are papilloma virus-free, indi-
cating that these carcinomas are independent of papil-
loma viruses, like other cervical carcinomas not
studied here [12,16,40,43-45,67,84]. As per Table 1 and
the literature, the remaining seven carcinomas studied
here are positive for various DNA sequences fromTable 1 Karyotypic and phenotypic individualities of the nine
Carcinoma HPV* Cell morphology and soci
C-33A – Cobblestone shapes; tight 3
HT-3 – Polymorphic; 3D
C-4II + Polygonal; growing as dens
CaSki + Polymorphic; 3D
HeLa-R + Round; tight 3D colony
HeLa-S + Fusiform; tight 3D colony
ME-180 + Triangular; high density
MS-751 + Polygonal; refractile; tight 3D
SiHa + Round or oval; dense gradu
SW-756-C1 + Round
SW-756-C2 + Fusiform
*HPV = Human papilloma virus; 3D = three dimensional.various papilloma virus strains and are thus potentially
virus-dependent [14,16-19,21,29,40,43,71].
Individual cell morphologies and sociologies
The cellular morphology and sociology of the nine carcin-
omas was studied microscopically on cells growing under
identical conditions in plastic culture dishes (Table 1).
Figure 2A shows that under our conditions the cells of the
near-diploid C-4II carcinoma had polygonal morphology
and grew as relatively flat, dense monolayers. Under the
same conditions the cells of near-diploid C-33A carcinoma
had cobblestone shapes and grew as tight three-dimensional
colonies (Figure 2B). The near-triploid ME-180 cells were
triangular and grew to high densities (Figure 2C), and the
near-triploid CaSki cells were polymorphic and also grew
three-dimensionally (Figure 2D).
Furthermore, we observed that the near-triploid HT-3
carcinoma cells were polymorphic and grew three-
dimensionally (Figure 3A), and that the MS-751 carcin-
oma cells were polygonal and refractile and grew as tight
three-dimensional colonies (Figure 3B). At variance, SiHa
carcinoma cells were round or oval-shaped and grew to
very high, gradually increasing three-dimensional densities
(Figure 3C).
Unexpectedly, in view of long passage history of the SW-
756 and HeLa carcinoma lines, we found that both lines
were morphologically heterogeneous. The morphological
pattern of native SW-756 consisted of fusiform and round
cell variants forming the dense three-dimensional cell
layers shown in Figure 4A. Micrographs of a fusiform and
a round SW-756 variant cloned from the native carcinoma
are shown in Figure 4B. Likewise we cloned a fusiform and
a round morphological cell variant from a commercial
stock of the HeLa carcinoma line. Figures 4C,D show
three-dimensional foci of the fusiform and the round cellcervical carcinomas of this study
ology Ploidy (Avg. Chromosome no)















Figure 2 Cellular morphologies of cervical carcinomas C-4II, C-33A, ME-180 and CaSki. The cells were grown in medium containing 5%
fetal calf serum and photographed at 120× magnification in cell culture dishes (Methods). The following individualities were observed:
(A) Polygonal C-4II cells forming a dense monolayer, (B) Cobblestone shaped and refractile of C-33A cells forming three-dimensional colonies,
(C) Oval or triangular ME-180 cells forming a dense refractile monolayer, and (D) Polymorphic CaSki cells forming a three-dimensional cell layer.
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logical HeLa variants isolated by us here are probably
the same as those originally cloned and karyotyped by
Marguerite Vogt in 1959 [85]. Thus both of these car-
cinomas consist of two morphologically distinct types ofA B
Figure 3 Cellular morphologies of cervical carcinomas HT-3, MS-751 a
The following individualities were observed: (A) Polymorphic HT-3 cells for
cells forming tight, three-dimensional colonies, and (C) Round to oval, refracells, which must be equally stable considering the long
passage history of these lines.
It is shown below that the morphological variants of
SW-756 and of HeLa are karyotypically closely related
(see, Do karyotypic variations or mutations alter theC
nd CaSki. The micrographs were prepared as described for Figure 2.
ming a near-three-dimensional cell layer, (B) Oval and refractile MS-751







Figure 4 Cellular morphologies of two morphological variants of the cervical carcinomas SW-756 and of HeLa. The micrographs were
prepared as described for Figure 2. The following individual cell morphologies and sociologies were observed: (A) Morphologically
heterogeneous SW-756 cells forming a mixed population of fusiform and round cell variants, (B) Clonal colonies of fusiform and round SW-756
variants, (C) A focus of fusiform HeLa cells, (D) A focus of round HeLa cells.
Table 2 Intrinsic drug‐resistances of cervical
carcinoma lines
Carcinoma-lines Methotrexate* Arabinocytidine* Puromycin*
C-33 - −/+ -
HT-3 - + -
CaSki - + +
MS-751 - + +
SW-56 - −/+ +
C-4II - −/+ -
HeLa - −/+ -
SiHa +/− + +/−
ME-180 - + +/−
*at 1 μg per 10^6 cells; + = confluent culture.
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suggests that cancer-specific karyotypic variations, rather
than mutations would have generated these morpho-
logical variants.
Individual intrinsic drug-resistances
The cervical carcinomas studied here also differed from
each other in intrinsic resistances to cytotoxic drugs.
According to the speciation theory this characteristic of
cancers is a direct consequence of the karyotypic origins
of cancers as follows: Since specific combinations of
multi-genic chromosomes generate new autonomous
cancer species, numerous new gene combinations with
new phenotypes are inevitably generated non-selectively,
which are not necessary for carcinogenesis – such as in-
trinsic drug-resistance [86-88]. Intrinsic drug-resistance
is thus a drug treatment-independent, individual pheno-
type of cancers.
Among the nine carcinoma lines tested here all but
one were found to be sensitive to methotrexate at 1 μg
per 10^6 cells, while SiHa appeared to be partially resist-
ant (Table 2). In contrast five, namely HT-3, CaSki
MS-751, SiHa, ME-180 were highly resistant and the
remaining four were modestly resistant to cytosine ara-
binoside at 1 μg per 10^6 cells. Further, four carcinomas,
namely CaSki, MS-751, SW-756, and ME-180 wereresistant to puromycin at 1 μg per 10^6 cells (Table 2).
These individual intrinsic drug resistances of the nine car-
cinomas are thus compatible with the prediction of non-
essential new cancer phenotypes by the speciation theory.
Section-specific conclusions. We conclude that all nine
distinct cervical carcinomas studied here have individual
cell morphologies and individual intrinsic resistances
against cytotoxic drugs. These results confirm the predic-
tion of the speciation theory that individual carcinomas
McCormack et al. Molecular Cytogenetics 2013, 6:44 Page 6 of 23
http://www.molecularcytogenetics.org/content/6/1/44have individual phenotypes, because they have individual
karyotypes.
A common viral etiology would instead have predicted
non-individual, common carcinoma-specific phenotypes
shared by the seven virus-positive carcinomas listed
above. Such virus-specific phenotypes would be lacking
in the two virus-free carcinomas C-33A and HT-3. How-
ever, no such virus-specific phenotypes were observed.
To test whether the individual phenotypes of cervical
carcinomas have karyotypic origins, we have next ana-
lyzed the karyotypes of the nine cervical carcinomas.
Individual clonal karyotypes of carcinomas
The speciation theory predicts that each cancer has an in-
dividual clonal karyotype. As a first test of the predicted
karyotypic individuality we compared in Figure 5 the
karyotypes of a normal female (Figure 5A) and of two
cervical carcinomas, namely HT-3 (Figure 5B) and CaSki
(Figure 5C). The comparisons show that both carcinomas
differ much from each other and from the normal female
karyotype in their total chromosome numbers, in the copy
numbers of most intact chromosomes, and in the pres-
ence of carcinoma-specific hybrid or marker chromo-
somes. We will show next that the copy numbers of the
intact and the marker chromosomes fall into a predomin-
ant clonal and into a minor non-clonal class.
We have determined karyotypic clonality by compar-
ing all chromosomes of 20 karyotypes of carcinomas in
three-dimensional arrays [47,58]. These arrays are 3-
dimensional tables, which list chromosome numbers on
the x-axis, chromosome copy numbers on the y-axis and
arrays of typically 20 karyotypes on the z-axis. Because
all chromosomes of karyotypes with identical or clonal
copy numbers form parallel lines in such arrays, it can
be seen at a glance, whether and to what degree arrayed
karyotypes are related. For example, the array of the 20
karyotypes of a normal human female, shown in Figure 6
(next paragraph), indicates at a glance that the copy
numbers of the chromosomes of all 20 normal cells are
two and thus clonal. Using such karyotype arrays we have
investigated the clonalities of all nine cervical carcinomas
studied here with the following results.
Individual clonal karyotypes of a normal female and of the
near-diploid carcinomas C-4II and C-33A
Figures 6 shows the karyotype arrays of a normal human
female and of the near-diploid carcinoma C-4II together
with a table listing the clonality of all C-4II chromo-
somes in %. As can be seen in the table, the average
chromosome number of C-4II was 43±1 and thus near
clonal (shown on the top of the table). The array and the
table further show that the copy numbers of the C-4II
chromosomes were 80 to 100% clonal and thus formed
mostly parallel lines. The non-clonal chromosomesconsisted (1) of intact chromosomes with non-clonal
copy numbers mostly oscillating in narrow margins of
±1 of clonal values, and (2) of two unique marker chro-
mosomes, which were present in 2 of 20 cells. By con-
trast, the 20 karyotypes of the normal female were 100%
clonal.
Figure 7 shows that the average chromosome number of
C-33A was 46±1 (see top of the attached table). The table
with the karyotype array also shows that 70 to 90% of the
copy numbers of the C-33A chromosomes were clonal,
and thus formed parallel lines in the array. The non-clonal
chromosomes consisted again of intact chromosomes with
non-clonal copy numbers and of five unique marker chro-
mosomes, which were present in 4 of 20 C-33A cells.
A comparison of the C-4II and C-33A arrays to each
other (Figures 6 and 7) shows at a glance that the karyotypes
of both carcinomas are highly clonal, and that they are indi-
vidually very different, much like two different signatures.
Moreover, the arrays of both carcinomas differ substantially
from that of the normal female.
The presence of non-clonal chromosomes in both carcin-
omas indicates ongoing chromosomal variation despite
overall clonality. In addition the C-33A displayed flexibility
of the karyotype as a whole, namely with regard to its ploidy.
An approximate two-fold polyploidization of the basic near-
diploid karyotype was observed in 3 per 20 cells. Other ex-
amples of polyploidizations in cancers are listed as cancer-
specific forms of karyotypic flexibility in Table 1, in figures
below, in the Background and in the literature
[21,46,50,55,58,89].
Thus the karyotype arrays of C-4II and C-33A confirm
the individualities and clonalities of the karyotypes of car-
cinomas predicted by the speciation theory. Moreover,
these karyotypes indicate a 1-to-1 ‘genotype-phenotype’
correspondence between individual clonal karyotypes and
cellular phenotypes (Figure 2A,B) of the two carcinomas:
‘one carcinoma – one karyotype’.
In the following we have analyzed the karyotype arrays
of the seven near-triploid cervical carcinomas introduced
above (Table 1). According to the speciation theory the
near-triploid carcinoma karyotypes should be more flex-
ible and thus more heterogeneous than the near-diploid
carcinomas, because more mitotic genes will be unbal-
anced in near-triploid than in near-diploid cancer karyo-
types [60,62,90] (Background, Figure 1).
Individual clonal karyotypes of the near-triploid carcinomas
SiHa, HT-, ME-180, CaSki, SW-756, HeLa and MS-751
The karyotype arrays of the seven near-triploid cervical carcin-
omas SiHa, HT-3, ME-180, CaSki, SW-756, HeLa and MS-
751 are shown in Figures 8, 9, 10, 11, 12, 13 and 14 respect-
ively. As shown in the tables attached to each array, the total
chromosome numbers of the near-triploid carcinomas were
near-clonal with averages ranging from 63 to 81. The tables
AC
B
Figure 5 Karyotypes of the normal human female (A) and the cervical carcinomas HT-3 (B) and CaSki (C). The comparisons show that both
carcinomas and the normal female had each distinct individual karyotypes. The karyotypes differed in their total chromosome numbers, the copy numbers
of most intact chromosomes and in carcinoma-specific hybrid or marker chromosomes. The chromosomes were color-coded as described in Methods.
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Cervical Carcinoma C-4II
Avg chromo no ± SD 43±1
Metaphases (n) 20
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der(X) short 1 (5)
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Figure 6 Karyotype arrays of a normal female and of the near-diploid cervical carcinoma C-4II. The figure shows the two karyotype arrays
and a table indicating that the total chromosome number of C-4II is 43±1, and is thus quasi-clonal. The table further shows the %-clonality of
all C-4II chromosomes. Karyotype-arrays are three-dimensional tables, which list the chromosome numbers of a given karyotype on the x-axis,
the copy numbers of each chromosome on the y-axis, and the number of karyotypes arrayed on the z-axis. In such arrays the chromosomes of
karyotypes with identical (clonal) copy numbers form parallel lines. The karyotype array with the attached table shows that 85 to 100% of the
copy numbers of the C-4II chromosomes are clonal, and thus form parallel lines in the array. The minority of non-clonal C-4II chromosomes included
(1) intact chromosomes with near-clonal copy numbers mostly oscillating in narrow margins of ±1 of clonal values and (2) two cells per 20 with unique
non-clonal marker chromosomes. The presence of non-clonal intact and marker chromosomes indicates ongoing karyotypic variation predicted by the
speciation theory (Background, Figure 1). By contrast, the karyotype array of a normal female shows 100%-clonality.
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cinoma is highly clonal and thus formed predominantly parallel
lines in the arrays shown in Figures 8, 9, 10, 11, 12, 13 and 14.
Thus far the karyotype arrays of nine cervical carcinomas
illustrate at a glance the individuality and clonality of each
carcinoma. Comparisons of the karyotypes of all carcinomas
with their cellular phenotypes (Figures 2, 3 and 4) further in-
dicate classical, individual ‘genotype-phenotype’ correlations
[85]. Thus all cervical carcinomas studied here confirm the
‘one carcinoma-one karyotype’ rule shown to apply to the
two near-diploid carcinomas C-4II and C-33A above [50].
As expected from the high degrees of aneuploidy (relative
to normal cells) of the seven near-triploid carcinomas, the
karyotypes of the near-triploid carcinomas (1) were moreflexible and thus more heterogeneous, (2) included much
higher numbers of clonal marker chromosomes, and (3) in-
cluded higher percentages of cells with unique, non-clonal
marker chromosomes than their near-diploid counterparts
(see Background and next section).
Carcinoma-specific chromosome recombination rates
In the following we have calculated individual “chromosome
recombination indices” for each of the nine cervical carci-
nomas based on the percentages of their cells with unique,
non-clonal marker chromosomes (Table 3). These percent-
ages ranged from a low of 10% in near-diploid C-4II cells to
a high of 95% in near-triploid CaSki cells. The dependence
of these chromosome recombination rates on the degree of













































































































der(1;18) s 1 (85)
1 0 der(1;18) l 1 (90)
2 2 (75) der(1;21) 1 (85)
3 1 (75) der(3;7) 1 (85)
4 2 (80) der(13;19) 1 (90)
5 2 (75) der(18;20) 1 (85)
6 2 (85) der(17?;14) 1 (85)
7 2 (85) der(15;22) 1(5)/2(5)
8 2 (85) der(22;15) 1 (10)
9 2 (85) der(22;2) 1 (10)
10 2 (85) Non-clonal Markers
11 2 (75) 3x1 per 20 cells:
12 2 (85) der(5) 1 (5)
13 1 (85) der(X;1) 1 (5)
14 1 (85) der(X;14) 1 (5)
15 2 (80) 1x2 per 20 cells:
16 2 (90) der(17;22;15) 1 (5)








Figure 7 Karyotype array of the near-diploid cervical carcinoma C-33A. The C-33A array with the attached table, prepared as described in
Figure 6, shows that the total chromosome number of C-33A is 46±1 and is thus quasi-clonal. The copy numbers of C-33A chromosomes were
70-90% clonal, forming parallel lines in the array. The non-clonal chromosomes included intact chromosomes with near-clonal copy numbers and
new non-clonal marker chromosomes, which were found in four of 20 cells. A comparison of the arrays of C-33A and of C-4II shows at a glance
that each carcinoma had an individual clonal karyotype.
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with the prediction of the speciation theory that chromo-
somal instability is proportional to the degree of aneuploidy
(Background).
The relatively low chromosome recombination index
of the near-triploid HeLa cell line shown in Table 3 may
reflect evolutionary time-dependent selective balancing
of mitosis genes in cancer species. The HeLa cell line
was the first to be established in vitro, and has been sta-
bly maintained in many laboratories since 1952 [91].
Section-specific conclusions. 1) All (100%) of the carcin-
omas tested here (Table 1) contained individual, clonal kar-
yotypes as predicted by the speciation theory (Figures 6, 7,
8, 9, 10, 11, 12, 13 and 14). The clonality of these carcin-
omas indicates that they derived from a single ancestral cell,
in which this clonogenic karyotype was formed. Since these
individual karyotypes correlated 1-to-1 with individual cell
morphologies (Figures 2, 3 and 4), individual intrinsic drug-
resistances (Table 2) and individual chromosome recombin-
ation indices (Table 3), and are not found in normal cells
(see Figure 6), we conclude that these karyotypes generated
and maintain the carcinomas studied here.
This conclusion agrees with our failure to find common
and thus non-individual karyotypic or phenotypic charac-
teristics shared by the seven virus-positive carcinomas. It
also explains the failures of many others to find commonvirus-specific cytogenetic markers predicted by the virus-
carcinoma theory [4,5,12,17-21,29,33,67].
2) The nine carcinoma karyotypes analyzed here also
confirmed the individual karyotypic flexibilities predicted
by the speciation theory (Background). Moreover the ar-
rays shown in Figures 6, 7, 8, 9, 10, 11, 12, 13 and 14
and the carcinoma-specific chromosome recombination
indices listed in Table 3 show that the karyotypic flexibil-
ities and corresponding karyotypic heterogeneities are
roughly proportional to the karyotypic complexity of
carcinomas, as predicted by the speciation theory.
3) With regard to the relevance of carcinoma karyo-
types to Pap-tests we deduce that karyotype analyses
could provide new, DNA content-independent distinc-
tions between carcinomas with near-normal DNA con-
tents and low Pap-grades such as C-4II and C-33A and
normal diploid hyperplastic tissues (Figures 6 and 7).
Among the Pap-tests with high, near-triploid DNA con-
tents, karyotype analyses could provide new information
like the chromosome recombination index as a measure
to grade malignancy.
Do karyotypic variations or mutations alter the
morphology and drug-sensitivity of carcinomas?
Since all nine individual carcinomas we analyzed contained
individual clonal karyotypes and phenotypes, we deduced


























































































































































Avg chromo no ± SD 66±4 In-tact chromos Clonal Markers Non-clonal Markers
Metaphases (n) 20 14 3 (85) der(5) 2 (95) 3x1 per 20 cells:
Chromos copy no (% clonal) 15 3 (50) der(19;20) 1 (90) der(14;5) 1 (5)
1 3 (90) 16 2 (75) der(X;9) 1 (90) der(7;12) 1 (5)
2 2 (95) 17 2 (70) der(17) 1 (85) der(8;19) 1 (5)
3 3 (80) 18 2 (95) der(16)long 1 (75) 2x2 per 20 cells:
4 2 (95) 19 2 (100) der(9;8;10) 1 (75) der(14;15) 1 (5)
5 3 (70) 20 3 (95) der(19;15) 1 (65) der(15;22) 1 (5)
6 2 (95) 21 2 (60) dmin(8) 1 (55) der(16;8) 1 (5)
7 2 (55) 22 4 (35) der(2;10) 1 (40) der(22;11) 1 (5)
8 2 (95) X 2 (60) der(6;3) 1 (15) 1x3 per 20 cells:
9 2 (90) Y 0 der(5;7) 1 (15) der(14;8) 1 (5)
10 2 (90) Clonal Markers der(15) short 1 (25) der(15;7) 1 (5)
11 3 (80) der(18;20) 1 (100) der(X;5) top 1 (30) der(6;4;6) 1 (5)
12 2 (80) der(12;6) 1 (95) der(X;5) bot 1 (10)
13 2 (90) i(21) 1 (95) der(7;16) 1 (10)
Figure 8 Karyotype array of the near-triploid cervical carcinoma SiHa. The SiHa array with the attached table, prepared as for Figure 6,
shows that the total chromosome number is quasi-clonal at 66±4. The copy numbers of 60-100% of the chromosomes were clonal forming
parallel lines in the array. The non-clonal chromosomes included intact chromosomes with near-clonal copy numbers and non-clonal marker
chromosomes, which were found in six of 20 cells. Comparison of the karyotype array of SiHa with those of the near-diploid carcinomas C-4II and
C-33A (Figures 6 and 7) shows at a glance that all three carcinomas have distinct, individual karyotypes.
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like the individual karyotypes that encode conventional spe-
cies. This theory predicts that carcinomas are subject to
phenotypic alteration by karyotypic variations, which would
thus be sub-speciations. Previously, we have found that
alterations in the sensitivity of cancers to toxic drugs
[55,88], and the origins of metastases [50,57] correlated
with karyotypic alterations.
By contrast, the viral and mutation theories of carcin-
omas postulate that poorly-defined viral sequences andgene mutations determine the phenotypes of carcinomas
(Background).
To distinguish between the mutation and speciation the-
ories as mechanisms of phenotypic variation, we compared
here the karyotypes of two matched pairs of carcinomas
differing in cell morphology, and of two matched pairs of
carcinomas differing in acquired drug-resistance.
As can be seen in Figure 12 the karyotypes of the SW-
756 clone with round cells (C1) differed from the karyotype
of the clone with fusiform cells (C2) (Figure 4A,B) in seven







































































































































































































































































































































































Avg chromo no ± SD (n=20) 68±3 (16/20), 133±1 (4/20) Clonal Markers der(19;8) 1 (40) 2x3 per 20 cells: 
Chromosomes copy no (% clonal) der(1;8;9) 1 (80) der(11;5) 1 (35) der(1;3;1) 1 (5)
1 1 (75) der(4;11) 1 (80) der(5;6) 1 (30) der(8;5) 1 (5)
2 2 (70) der(2;9) 1 (85) der(13;16) 1 (35) der(5;3) 1 (5)
3 1 (75) i(14p) 1 (85) der(18;8) 1 (45) min(2) 1 (5)
4 1 (85) der(1;12short) 1 (85) der(X;5;12) 1 (15) der(20p) 1 (5)
5 3 (45) der(1;12long) 1 (80) der(19;5) 1 (15) der(20q) 1 (5)
6 1 (75) dic(10;15) 1 (75) der(2) short 1 (25) 2x5 per 20 cells: 
7 2 (75) der(4;7) 1 (80) der(18;2) 1 (15) der(2;20) 1 (5)
8 1 (70) der(22;11) 1 (80) der(9;1;3) 1 (10) der(5;15) 1 (5)
9 1 (75) der(1;9) 1 (70) der(3) 1 (10) der(15;20) 1 (5)
10 1 (75) der(3;12) 1 (85) der(7q) 1 (10) der(7;12) 1 (5)
11 2 (50) der(6;20) 1 (70) Non-Clonal Markers der(10) 1 (5)
12 2 (80) der(18;X) 1 (80) 4x1 per 20 cells: der(X;7) 2 (5)
13 1 (80) der(17;16) 1 (75) der(1;11) 1 (5) der(7) 2 (5)
14 2 (50) der(6;13) 2 (55) der(15;2) 1 (5) der(14;12) 1 (5)
15 2 (80) der(9;16) 2 (70) der(5;6) short 1 (5) der(X) 2 (5)
16 1(15)/0(85) der(19;16) 2 (50) dmin(4) 1 (5) der(21;X) 1 (5)
17 2 (75) der(5;X) 1 (65) 2x2 per 20 cells: 1x7 per 20 cells:
18 1 (80) der(11) short 1 (70) der(19;21) 1 (5) der(7;22) 1 (5)
19 2 (60) der(10;16;6) 1 (75) der(2;5;6) 1 (5) der(15?;2) 1 (5)
20 4 (55) der(18;11) 1 (75) der(21;7;5) 1 (5) der(22;2) 1 (5)
21 2 (60) der(15;2) 1 (75) der(12;13) 1 (5) der(7p) 1 (5)
22 2 (50) min(16) 1 (55) der(3p) 1 (5)
X 2 (80) der(3;6) 1 (60) der(9p) 1 (5)
Y 0 der(12;7;5) 1 (60) min(9) 1 (5)
Figure 9 Karyotype array of the cervical carcinoma HT-3. The HT-3 array with the attached table shows that the total chromosome number
is quasi-clonal at 68±3. The copy numbers of 60-85% of the chromosomes were clonal forming parallel lines in the array. The non-clonal
chromosomes included intact chromosomes with near-clonal copy numbers and new non-clonal marker chromosomes, which were found in 14
out of 20 cells. Comparison of the karyotype array of HT-3 with those of the three carcinomas shown above in Figures 6, 7 and 8 reveals at a
glance that all four carcinomas have distinct individual karyotypes.
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round clone C1-specific and four fusiform clone C2-
specific marker chromosomes.Likewise we show in Figure 13 that the karyotype of the
HeLa R clone with round cells differed from the karyotype
of the HeLa clone S with fusiform cells in the clonal copy


















































































































































































































































































Avg chromo no ± SD (n=20) 61±2 Clonal Markers Non-clonal Markers der(20;15;12) 1 (5)
Chromosomes copy no (% clonal) der(10;16) 1 (100) 9x1 per 20 cells: der(7;14;10) 1 (5)
1 2 (100) der(9;7) 1 (100) der(X;14) 1 (5) der(1;5) 1 (5)
2 2 (95) der(8;5) 1 (95) der(3;4) 1 (5) 1x5 per 20 cells:
3 2 (70) der(9;7;3) 1 (95) der(3;7;9;17) 1 (5) der(5)m 1 (5)
4 2 (100) der(17;15) 1 (100) der(9q) 1 (5) der(22;X) 1 (5)
5 2 (80) der(15;12) 1 (90) der(2;3) 1 (5) der(19p) 1 (5)
6 2 (90) der(17;12) ? 1 (95) der(13;X) 1 (5) der(19q) 1 (5)
7 1 (100) der(15;17) 1 (90) der(5;10) 1 (5) der(5)t 1 (5)
8 1 (85) der(2;16) 1 (90) der(9;X) 1 (5)
9 3 (80) der(22;8) 1 (65) der(20;14;16?) 1 (5)
10 1 (95) der(9;5) 1 (70) 5x3 per 20 cells:
11 3 (100) der(2;7;3) 1 (70) der(2) 1 (5)
12 2 (100) der(5;14) 1 (75) der(5;19) 1 (5)
13 2 (85) der(9;14) 1 (65) der(6) 1 (5)
14 2 (80) der(16;2?) 1 (60) der(3;9) 1 (5)
15 1 (90) der(9;14;10;16) 1 (20) der(5;15) 1 (5)
16 2 (90) der(2;16)b 1 (25) der(X;21) 1 (5)
17 2 (85) der(8;7;3) 1 (30) der(9;14;6) 1 (5)
18 2 (100) der(16cen) 1 (15) der(9;6) 1 (5)
19 3 (85) der(3;5) 1 (25) der(14;2;16) 1 (5)
20 3 (90) der(9;14)b 1 (10) der(14;5) 1 (5)
21 2 (85) der(5;9;17) 1 (10) der(5) 1 (5)
22 1 (75) der(17;9) 1 (10) del(6p) 1 (5)
X 3 (60) der(9;17;10) 1 (10)
Y 0
Figure 10 Karyotype array of the cervical carcinoma ME-180. The ME-180 array with the attached table shows that the total chromosome
number is quasi-clonal at 63±2. The copy numbers of 60-100% of the chromosomes were clonal forming parallel lines in the array. The non-clonal
chromosomes included intact chromosomes with near-clonal copy numbers and new non-clonal marker chromosomes found in 16 of 20 cells.
Comparison of the karyotype array of ME-180 with those of the four carcinomas shown above in Figures 6, 7, 8 and 9 reveals again at a glance that all
five carcinomas have distinct individual and clonal karyotypes.
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Avg chromo no ± SD 75±3 Clonal Markers der(6;3) 2 (60) Non-clonal Markers 6x4 per 20 cells: 3x5 per 20 cells: 1x8 per 20 cells:
Metaphases (n) 20 der(1;4) 1 (100) der(3;5) 1 (55) 1x1 per 20 cells: der(5;8) small 1 (5) der(6;10) 1 (5) der(8;12) 1 (5)
Chromosomes copy no (% clonal) der(11;14) 1 (100) der(5;21) 2 (65) der(6;5?) 1 (5) der(20;21) 1 (5) der(10;16) 1 (5) der(6;2) 1 (5)
1 2 (100) der(8;X) 1 (100) der(15;18) 1 (25) 1x2 per 20 cells: der(X;5;14) 1 (5) der(5p) 1 (5) der(2;12) 1 (5)
2 2 (65) der(2;7) 1 (95) der(11) long 1 (20) der(10;18) 1 (5) der(11;X;14) 1 (5) der(9) 1 (5) der(10) 1 (5)
3 1 (55) der(7;17) 1 (95) der(10;19) 1 (20) der(14;18) 1 (5) der(2;6) 1 (5) der(11;9) 1 (5) der(3;6) 1 (5)
4 2 (65) der(7;21) 1 (95) der(7;2) 1 (20) 6x3 per 20 cells: der(11;13;14) 1 (5) der(14;22) 1 (5) der(18;2) 1 (5)
5 1 (90) der(10;21) 1 (95) der(2;16) b 1 (20) der(6;3;5) 1 (5) der(4;10) 1 (5) der(11;13) 1 (5) der(17;6) 1 (5)
6 3 (50) der(5;8) 2 (90) der(4;22;13) 1 (20) der(2;11;13;15) 1 (5) der(16;13) 1 (5) der(7;5;3) 1 (5) der(3q) 1 (5)
7 2 (80) der(3;5) long 1 (90) der(5;14) 1 (20) der(11;20) 1 (5) i(18q) 1 (5) der(22;3) 1 (5)
8 2 (60) der(5;X) 1 (85) der(4;14) 1 (15) der(3;20) 1 (5) der(6;13) 1 (5) der(19;1) 1 (5)
9 4 (75) der(2;16) 1 (85) der(15;21) 1 (10) der(17;8?) 1 (5) der(6;16) 1 (5) der(4;19) 1 (5)
10 1 (95) der(13;11) 1 (95) der(19;5) 1 (10) der(6q) 1 (5) der(20;7) 1 (5) der(6;10) 1 (5)
11 1 (55) der(12p) 1 (85) der(7;11) 1 (10) der(5;11) b 1 (5) der(11;3) 1 (5) der(12?;13) 1 (5)
12 2 (95) der(18;12q) 1 (85) der(8p) 1 (10) der(11;15) 1 (5) der(19;20;6) 1 (5) der(16;20) 1 (5)
13 1 (90) der(15;14) 2 (85) der(11;3) 1 (10) der(22;12) 1 (5) i(6;3) 1 (5) der(19;4) 1 (5)
14 1 (75) i(16q) 1 (80) der(X;2;7) 1 (15) der(9;10) 1 (5) der(3p) 1 (5) 1x6 per 20 cells:
15 1 (95) der(13) 1 (75) der(1;3) 1 (10) der(12;21) 1 (5) der(7;1) 1 (5) der(8q) 1 (5)
16 1 (85) der(14;11;13;15) 1 (80) der(7;11;13;15) 1 (10) der(22;10) 1 (5) der(1;19) 1 (5) der(6;9) 1 (5)
17 2 (70) der(15;6) 1 (100) der(5;7) 1 (10) der(19;3) 1 (5) der(4;12) 1 (5) der(13;11;16) 1 (5)
18 2 (80) der(17;2) 1 (90) der(18) 1 (10) der(21;1;15) 1 (5) der(20;22) 1 (5) i(5;8) 1 (5)
19 3 (45) der(5;16) 1 (80) der(3) 1 (10) der(6;11) 1 (5) der(11;17) 1 (5) i(X;2;7) 1 (5)
20 4 (45) der(19;17) 1 (75) der(9;20) 1 (10) der(2;9) 1 (5) der(5;11) 1 (5) dmin(9) 1 (5)
21 1(10)/0(90) der(10;20) 1 (75) der(8;17) 1 (20) der(3;16;11) 1 (5) der(14;20) 1 (5)
22 2 (70) der(11;22;14) 1 (70) der(11;8) 1 (10) der(17;7;17) 1 (5) der(6;15;8) 1 (5)
X 1 (95) der(10;5) 1 (70) der(19;20) 1 (10)
Y 0 der(2) short 1 (65) der(8;11) 1 (10)
Figure 11 Karyotype array of the cervical carcinoma CaSki. The CaSki array with the attached table shows that the total chromosome
number is quasi-clonal at 75±3. The copy numbers of 65-100% of the chromosomes were clonal forming parallel lines in the array. The
non-clonal chromosomes included intact chromosomes with near-clonal copy numbers and new non-clonal marker chromosomes found in 19
of 20 cells. Comparison of the karyotype array of CaSki with five carcinomas shown above in Figures 6, 7, 8, 9 and 10 shows at a glance that all
six carcinomas have distinct individual and clonal karyotypes. Note, about 60 non-clonal marker chromosomes of the 20 karyotypes of CaSki listed
in the table are not shown in the graph to allow sufficient resolution for the clonal chromosomes.




































































































































































































































































































Cervical Carcinoma SW-756 
Neoplastic clones C1 C2 C1 C2 C1 C2 
Avg chromo no ± SD (n=20) 80±3 82±2 Clonal Markers Non-Clonal Markers 
Chromosomes Copy no (% clonal) der(11;7) 1 (100) 1 (100) 1x1 per 20 cells: 
1 3 (55) 3 (90) der(16;15) 1 (100) 1 (100) der(5)tin 1 (5) 0 
2 1 (100) 3 (95) der(15;11) 1 (100) 1 (100) 1x2 per 20 cells: 
3 3 (85) 3 (80) der(17;19) b 1 (100) 1 (95) dmin(9) 1 (5) 0 
4 3 (90) 2 (100) i(12p) 1 (100) 2 (85) dmin(1) 1 (5) 0 
5 3 (85) 3 (95) i(13q) 1 (95) 1 (95) 
6 4 (90) 4 (95) der(X) 1 (90) 1 (90) 1x3 per 20 cells: 
7 4 (90) 4 (95) der(5) 1 (90) 1 (90) der(16;18) 1 (5) 0 
8 2 (95) 3 (90) der(14;20) 1 (90) 1 (90) der(6) 1 (5) 
9 3 (90) 3 (100) der(8;2) 2 (85) 1 (90) der(5;22) 1 (5) 
10 3 (90) 3 (95) i(2q) 1 (100) 0 3x1 per 20 cells: 
11 2 (100) 2 (100) der(6;17) 1 (100) 0 der(2;X) 0 1 (5) 
12 4 (85) 2 (90) der(5;21) 1 (90) 0 der(7;X) 0 1 (5) 
13 1 (100) 2 (95) der(3;13) 1 (90) 0 der(1;21) 0 1 (5) 
14 2 (100) 2 (90) der(5q) 1 (85) 0 2x2 per 20 cells: 
15 2 (95) 2 (100) der(X) 1 (10) 0 der(5;13) 0 1 (5) 
16 2 (95) 2 (95) i(12q) 0 1 (100) der(10) 0 1 (5) 
17 3 (95) 2 (90) der(5;1) 0 1 (100) der(12;X) 0 1 (5) 
18 3 (80) 3 (90) der(17;19) 0 1 (95) der(X;12) 0 1 (5) 
19 3 (90) 3 (100) der(9) 0 1 (90) 
20 5 (85) 5 (90) 
21 3 (90) 3 (85) 
22 3 (70) 3 (95) 
X 3 (65) 5 (75) 
Y 0 0 
Figure 12 (See legend on next page.)
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Figure 12 Karyotype arrays of two morphological variants of the cervical carcinoma SW-756. The table of chromosomes and the arrays
of the SW-756 variants show that the total chromosome number of the round (C1) SW-756 clone is 80±3 and that of the fusiform (C2) clone
is 82±2. Thus both clones are quasi-clonal. The table also shows that copy numbers of 55-100% of chromosomes of both clones formed
parallel lines in the arrays. Non-clonal chromosomes included intact chromosomes with near-clonal copy numbers and new non-clonal marker
chromosomes found in three and five of 20 SW-756 cells respectively. Comparison of the karyotype arrays of the two morphological SW-756
variants indicate that the two clones are phylogenetically closely related, but differed in the clonal copy numbers of seven intact
chromosomes, and in five highly clonal round C1-specific and four fusiform C2-specific markers. Comparison of the SW-756 arrays with the
arrays of the six carcinomas shown above in Figures 6, 7, 8, 9, 10 and 11 reveals again at a glance that all seven carcinomas have individual
clonal karyotypes.
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and eight S-specific marker chromosomes.
Similarly we show in Figure 13 that the karyotype of
the methotrexate-resistant HeLa S clone (0.5 μg per
10^6 cells) differed from the karyotype of the drug-
sensitive HeLa S clone in the copy numbers of 10 intact
chromosomes and the loss of seven parental markers.
Likewise we show in Figure 14 that the karyotype of the
methotrexate-resistant MS-751 clone differed from the
karyotype of the drug-sensitive clone in the copy numbers
of eight intact chromosomes, and the loss of one and the
gain of 4 new clonal marker chromosomes.
By chance, we found that the four new methotrexate-
specific MS-751 marker chromosomes were derived
from one non-clonal cell of the native MS-751 carcin-
oma (Figure 14). To emphasize this accidental discov-
ery, we flagged these markers in Figure 14 by an asterisk
in both cases. Thus drug-resistance in this case was
probably generated in part by the clonal selection of a
non-clonal variant of the drug-sensitive native carcin-
oma MS-751. This confirms a previous example for
phenotypic variation by selection of a non-clonal
chromosome by Heng et al. [51,56].
Section-specific conclusions. 1) In sum carcinoma-specific
phenotypes vary 1-to-1 with carcinoma-specific karyotypes.
In view of this we conclude that karyotypic alterations
or subspeciations cause alterations of the cell morphology
and drug-sensitivity of carcinomas, rather than muta-
tions or viral sequences. According to Marguerite Vogt
in 1959, “a one-to-one relationship between karyotype
and phenotype … favor(s) strongly the assumption of
a causal relationship between karyotype and phenotype
in a tissue culture line of human neoplastic cells, the
strain HeLa” – much as we propose here now, 54 years
later [85].
2) It could be argued, however, that the morphological
variants of SW-756 and of HeLa, and the drug-resistant
variants of HeLa and of MS-751 studied here were each
caused by undetected mutations of cellular or viral
genes, but were inadvertently accompanied by new clonal
karyotypic variations. But it is unlikely that in all four of
these variations undetected causal mutations were inad-
vertently accompanied by karyotypic alterations that wereclonally stable in subsequent passages. It would follow that
specific karyotypic variations, rather than mutations gen-
erated the morphological and drug-resistant carcinoma
variants.
Copy numbers of hundreds of over- and under-expressed
mRNAs of individual carcinomas are proportional to the
copy numbers of their chromosomes
Several researchers have recently investigated the trans-
criptomes of cervical carcinomas. As is the rule with other
cancers (Background), the transcriptomes of cervical carcin-
omas consist of hundreds of individually over- and under-
expressed normal mRNAs [33,45,68-72]. In agreement with
the individuality of the transcriptomes of carcinomas,
no consistent or “recurrent” carcinoma-specific “drivers”
emerged in searches for common carcinoma-specific
transcripts [33,45,69,70].
Moreover, it has not been possible to identify consist-
ent transcriptomes of cervical carcinomas with HPV-
functions [33,45], “likely representing common signaling
pathways triggered by HPV” [68] and thought to have
“potential value of targeting E6 and E7 function … in the
treatment of HPV(+) cancers” [45]. This is again consist-
ent with the absence of a common, virus-specific karyo-
typic pattern in the different virus-positive carcinomas
described in section two above.
In view of this we propose here that the individual karyo-
types of cervical carcinomas encode the complex, individual
transcriptomes of carcinomas (Figure 1). This proposal is
consistent with several independent studies, which have
shown that the copy numbers of the mRNAs of cancers
are directly proportional to the copy numbers of the cor-
responding chromosomes [71,73-75,77,78]. Accordingly
Landry et al. have even shown by quantitative sequence
analyses that the copy numbers of all HeLa mRNAs are
exactly proportional to the copy numbers of the corre-
sponding chromosomes. In view of this they concluded
that there is “no dosage compensation” for the chromo-
some copy number-dependent dosage of HeLa mRNAs
[71]. Adey et al. have just confirmed this conclusion [72].
Section-specific conclusions. We conclude that individual
karyotypes of cervical carcinomas encode their highly com-






Avg chromo no. 
SD (n=20) 71±3 67±2 66±6
Chromosome Copy Number (% Clonal)
1 3 (85) 3 (95) 3 (95)
2 1 (95) 1 (100) 1 (90)
3 1 (100) 1 (95) 1 (100)
4 2 (85) 2 (100) 2 (95)
5 2 (85) 2 (95) 3 (85)
6 1 (100) 1 (95) 1 (70)
7 3 (100) 3 (100) 3 (70)
8 2 (95) 3 (85) 3 (70)
9 1 (95) 1 (55) 2 (90)
10 2 (95) 3 (100) 3 (85)
11 2 (95) 2 (100) 2 (90)
12 2 (85) 2 (90) 3 (95)
13 2 (100) 0 0
14 3 (85) 1 (100) 2 (100)
15 4 (90) 4 (55) 3 (75)
16 3 (85) 3 (95) 2 (80)
17 3 (90) 3 (60) 3 (50)
18 2 (95) 2 (80) 3 (70)
19 1 (90) 2 (70) 1 (75)
20 2 (100) 2 (100) 2 (75)
21 2 (100) 2 (90) 1 (95)
22 1 (95) 1 (75) 2 (80)
X 2 (90) 2 (100) 2 (100)
Y 0 0 0
Clonal Markers
der(2:6) 1 (100) 1 (100) 1 (95)
der(3;5) 1 (95) 1 (100) 1 (95)
der(6;1) 1 (100) 1 (100) 1 (100)
der(5;3;8) 1 (100) 1 (100) 1 (95)
der(5) 2 (90) 2 (100) 2 (85)
der(17;11;17) 1 (100) 1 (100) 1 (90)
der(6) 1 (95) 1 (95) 1 (70)
der(9;20) 1 (100) 1 (95) 1 (85)
der(20;22) 1 (95) 1 (95) 1 (70)
der(5;9) 1 (85) 1 (90) 1 (85)
der(14;17) 1 (95) 1 (100) 0
der(18) 1 (90) 1 (90) 0
der(22;5) 1 (90) 1 (65) 0
der(9) 1 (90) 1 (50) 0
der(17;19) 1 (95) 1 (40) 0
der(19;20) 1 (85) 1 (30) 0
der(2;3) 0 1 (100) 1 (100)
der(3;12) 0 1 (100) 1 (95)
der(12;14) 0 1 (100) 1 (90)
i(13) 0 1 (100) 1 (85)
der(6;1;9) 0 1 (100) 1 (70)
der(8;13;19) 0 1 (95) 1 (100)
der(15) 0 1 (10) 1 (5)
der(12) 0 1 (90) 0
der(12;3;8) 1 (100) 0 0
der(1;3) 1 (100) 0 0
der(X;16) 1 (100) 0 0
der(10;2) 1 (100) 0 0
der(13;19) 1 (95) 0 0
der(8;11) 1 (95) 0 0
der(3;2;10) 1 (95) 0 0
Non-clonal Markers
2x1 per 20 cells:
der(19;14) 1 (5) 0 0
der(?) 1 (5) 0 0
4x1 per 20 cells:
der(3;18) 0 1 (5) 0
der(18;19) 0 1 (5) 0
min(8) 0 1 (5) 0
der(17)? 0 1 (5) 0
4x1 per 20 cells:
der(9;11;9) 0 0 1 (5)
der(20;22;1;6) 0 0 1 (5)
der(5;15) 0 0 1 (5)
der(17;5) 0 0 1 (5)
4x2 per 20 cells:
der(11;17) 0 0 1 (5)
der(6;22;5) 0 0 1 (5)
der(6;9;19) 0 0 1 (5)
der(?) 0 0 1 (5)
der(9;11;20) 0 0 1 (5)
der(?;20) 0 0 1 (5)
der(16;9;20) 0 0 1 (5)
der(1) 0 0 1 (5)
1x4 per 20 cells:
der(7;17) 0 0 1 (5)
der(6;9;8) 0 0 1 (5)
der(9;16) 0 0 1 (5)
der(2) 0 0 2 (5)
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Karyotype-arrays of HeLa-R, HeLa-S and HeLa-S-MTX resistant
Figure 13 (See legend on next page.)
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Figure 13 Karyotype arrays of two morphological variants and a methotrexate-resistant variant of the cervical carcinoma HeLa. The
table of the chromosomes and the arrays of HeLa variants show that the total chromosome number of the morphological variant R (round) is
71±3, that of the morphological variant S (fusiform) is 67±2, and that of the methotrexate-resistant clone of S is 66±6. These chromosome
numbers are thus all quasi-clonal. The copy numbers of 55-100% of chromosomes were also clonal. Non-clonal chromosomes included intact
chromosomes with near-clonal copy numbers and new non-clonal marker chromosomes, which were found in two and four of the established
morphological HeLa variants and in nine of 20 cells of the new methotrexate-resistant HeLa S clone. Comparisons of the karyotype arrays of the
three HeLa variants show that all three variants are phylogenetically closely related subspecies with the following distinctions: The morphological
variant R differed from S in five copy numbers of intact chromosomes and in 7 R-specific and 8 S-specific marker chromosomes. The
methotrexate-resistant S clone differed from the native S variant in nine copy numbers of intact chromosomes and in the loss of seven 30-90%
clonal S markers. Comparison of the HeLa arrays with the arrays of the seven distinct carcinomas shown in Figures 6, 7, 8, 9, 10, 11 and 12 reveals
again at a glance that all eight carcinomas tested so far have individual and clonal karyotypes.
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mRNAs and the copy numbers of the corresponding chro-
mosomes of HeLa cells described by Landry et al. [71] and
Adey et al. [72] as Rosetta stones of functional evidence for
our theory.Additional karyotype-dependent characteristics of cervical
carcinomas
All cancers have common characteristics in addition to
those studied here, as for example (a) autonomy, (b)
immortality and (c) the ability to metastasize [49,59].
Indeed all nine carcinomas studied here are autono-
mous and immortal in cell culture [84] and three of
these, HT-3, MS-751 and CaSki have been described to
form metastases in vivo [21].
The following reasons indicate that these cancer-
specific commonalities are properties of common cancer-
specific karyotypes rather than of common mutations or
virus-derived sequences: (a) Autonomy is the primary
characteristic of a species conferring reproductive inde-
pendence of the parental species. As we pointed out
above, the origin of carcinoma-specific autonomy coin-
cides with that of the clonal origins of carcinoma-specific
karyotypes (Background, Figure 1, Results, sections two
and three). (b) Immortality of carcinomas has been re-
duced to karyotypic flexibility, which generates new vari-
ants constitutively to replace the inevitable chromosomal
and genetic mutations that accumulate over time [58]
(Figure 1). As described in the Background karyotypic
flexibility and the corresponding cancer-specific clonal
heterogeneity are direct consequences of the congenital
aneuploidy of all cancers. (c) Metastasis has also been
reduced to karyotypic flexibility generating metastatic
sub-species of carcinomas with variant tissue-tropisms
[50,57,59] – much as karyotypic flexibility generated the
drug-resistant and morphological variants described above
in Figures 12, 13 and 14.
Section-specific conclusions. Common carcinoma-specific
characteristics like autonomy and karyotypic flexibility,
which generate immortality and metastases, lend add-
itional support to the theory that carcinoma-specifickaryotypes are sufficient to create and maintain carcin-
omas, independent of mutations and sequences of latent
viruses.
Discussion
1) New individual karyotypes encode carcinomas - much like
the individual karyotypes that encode conventional species
Since the individual clonal karyotypes of nine carcinomas
correlated 1-to-1 and co-varied 1-to-1 with the complex
individual transcriptomes and phenotypes of these carci-
nomas, we conclude that individual clonal karyotypes en-
code these carcinomas, much like the individual clonal
karyotypes that encode conventional species. In sum this
evidence provides genetic and functional proof for the
speciation theory of carcinomas.
Indeed 1-to-1 correlations between phenotypes and karyo-
types are the classical genetic basis of defining phylogenetic
identities and relationships between conventional species
[92,93]. Thus the endless individual “DNA contents” and cor-
responding individual karyotypes, grades of malignancy and
histological phenotypes of the carcinomas studied here and
of those first described by Papanicolaou et al. [1], each sup-
port the conclusion that carcinomas are species of their own.
Our conclusion that transcriptionally very active and com-
plex individual karyotypes, instead of mutations or latent
viral sequences, encode carcinomas thus explains our fail-
ures and those of numerous others to find common,
virus-specific karyotypic or phenotypic characteristics in pap-
illoma virus-positive carcinomas [5,12,16,18-21,29,33,67,70].
The carcinoma-species-theory also explains the recent
finding that “HPV status … showed no correlation to out-
come” [70].
Above all there is no direct functional evidence that cervical
carcinomas depend on (1) the plethora of “passenger muta-
tions” and “single nucleotide polymorphisms”, which are
found in all cancers and normal cells by genome sequencing
[94-96], or on (2) the defective and latent papilloma viral se-
quences (Background), which are found in 50 million or
about 30% of healthy American females [37]. If carcinomas
would depend on papilloma virus functions they would be
immunogenic and subject to anti-viral immunity, which is
not observed [31,34]. Indeed, the occurrence of papilloma
Karyotype-arrays of  
carcinoma MS-751 














































































































































































































































































































































































































































Native MTX r Native MTX-r Native MTX-r Native MTX r
Avg chromo no. 
±SD 75±10 75±5 Clonal Markers Clonal Markers Non-Clonal Markers
Chromosome Copy Number (% clonal) der(12;8) 2 (95) 2 (95) der(6) - 1 (11) 5x1 per 20 cells: 
1 4 (75) 3 (79) der(3;8) 2 (90) 2 (95) der(2;22;11) - 1 (11) der(3;14) - 1 (5)
2 2 (95) 4 (84) der(X;5) 2 (85) 2 (84) der(4) - 1 (11) der(8) - 1 (5)
3 2 (80) 2 (95) der(6;18) 2 (85) 2 (63) der(14;15) short - 1 (16) der(1;12) - 1 (5)
4 2 (85) 2 (100) der(14;7) 2 (80) 2 (63) der(22;11) short - 1 (26) der(5) - 1 (5)
5 3(45) / 4(45) 3 (53) der(8;18) 2 (75) 2 (53) Non-clonal Markers der(2;16) - 1 (5)
6 2 (40) 1 (58) der(21;22) 2 (75) 2 (58) 6x1 per 20 cells: 1x2 per 20 cells: 
7 2 (90) 2 (84) der(20;21) 2 (70) 2 (74) der(7) 1 (5) - der(5;21) - 1 (5)
8 1(45) / 2(45) 2 (74) der(7;21;19) 1 (65) 1 (95) der(17;18;22;15) 1 (5) - der(9) - 1 (5)
9 4 (75) 3 (68) der(17) 2 (60) 1 (74) der(15;6) 1 (5) - 2x3 per 20 cells: 
10 4 (85) 4 (68) der(18;22;15) 2 (35) 1 (84) der(20;22;15;X) 1 (5) - der(22;11;18) - 1 (5)
11 2 (80) 2 (53) der(6) 2 (40) 1 (68) dmin(16) 1 (5) - del(3q) - 1 (5)
12 2 (70) 2 (68) der(14;6) 2 (30) 1 (74) der(18) 1 (5) - der(X) - 1 (5)
13 2 (95) 2 (84) der(22;11) 2 (30) 1(53)/0(47) 2x2 per 20 cells: der(6;22) - 1 (5)
14 0(45) / 1(30) / 2(25) 1 (95) der(5;8) 1 (40) 1 (26) der(7;19) 1 (5) - der(6) - 1 (5)
15 3 (60) 3 (79) i(11q) 1 (35) 1 (16) der(1;5) 1 (5) - der(10) - 1 (5)
16 4 (65) 4 (58) der(20;22;15) 1 (35) 1 (11) der(14;15) 1 (5) - 3x4 per 20 cells:
17 2 (70) 2 (63) der(3;22;15) 1 (30) 1 (5) der(1) 1 (5) - der(X;15) - 1 (5)
18 2 (65) 3 (74) der(2;22) 2 (90) - 1x6 per 20 cells: der(9;14) - 1 (5)
19 2 (80) 2 (89) der(20) 1 (35) - der(1;5;3) 1 (5) * * der(17;16) - 1 (5)
20 2 (55) 2 (84) der(15;18) 1 (30) - der(5;1) 1 (5) * * der(16;17) - 1 (5)
21 0 0(95) / 1(5) der(11;22;9) 2 (10) - der(11;20) 1 (5) * * del(2p) - 1 (5)
22 0 0(95) / 1(5) der(18;X) 2 (10) - der(22;15) 1 (5) * * der(14;21) - 1 (5)
X 2 (75) 2 (79) der(11;14) 1(5) / 2(5) - der(6;?) 1 (5) - min(8) - 1 (5)
Y 0 0 der(1;5;3) 1 (5) * 1 (89) der(14;X) 1 (5) - min(19) - 1 (5)
der(5;1) 1 (5) * 1 (89) der(11;1) - 1 (5)
der(11;20) 1 (5) * 1 (84) der(2;4) - 1 (5)
der(22;15) 1 (5) * 1 (79) der(10;15) - 1 (5)
der(16) - 1 (5)
Figure 14 (See legend on next page.)
McCormack et al. Molecular Cytogenetics 2013, 6:44 Page 18 of 23
http://www.molecularcytogenetics.org/content/6/1/44
(See figure on previous page.)
Figure 14 Karyotype arrays of the native and a methotrexate-resistant variant of the near-triploid cervical carcinoma MS-751. The table
of the chromosome and the arrays of the two MS-751 variants show that the chromosome number of the native MS-751 variant is 75±10 and
that of the methotrexate-resistant variant is 75±5. They are thus both quasi-clonal. The table also shows that the copy numbers of 60-100%
chromosomes were clonal forming parallel lines in the karyotype arrays. Non-clonal chromosomes were intact chromosomes with near-clonal
copy numbers and new non-clonal marker chromosomes, which were found in nine of 20 cells of the native MS-751 variant and in 11 of 20 cells
of the drug-resistant clone. Comparison of the arrays of the two MS-751 variants shows at a glance that the two variants are karyotypically closely
related. They differed from each other in the copy numbers of five clonal intact chromosomes, and in three 30–90%-clonal native MS-751-specific
markers, and in four 80-90%-clonal methotrexate resistance-specific markers. By chance, the four clonal methotrexate-specific MS-751 marker
chromosomes, flagged with asterisks, were all found in one non-clonal cell of the native MS-751 carcinoma (See also section three). Comparison
of the MS-751 arrays with the arrays of the eight carcinomas shown in Figures 6, 7, 8, 9, 10, 11, 12 and 13 reveals again at a glance that all nine
carcinomas have distinct individual clonal karyotypes. Note, about 25 non-clonal marker chromosomes of the 20 karyotypes of the MS-751
variants listed in the table are not shown in the graphs to allow sufficient resolution for the clonal chromosomes.
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that cervical carcinomas are virus-independent (Background).
In view of this the clonal, but nonidentical viral sequences
and cellular mutations found recently in individual cancers by
whole genome sequencing appear to be non-carcinogenic,
preneoplastic mutations, which became clonal accidentally by
subsequent evolutions of clonogenic cancer-specific karyotypes.
Because of their lack of carcinogenic function such pre-
neoplastic mutations have been termed “passenger muta-
tions” [95-97] or “implausible” mutations [98]. Cancer cells
are thought to acquire such individual passenger or implaus-
ible mutations during their long preneoplastic histories ei-
ther from conception to cancer [95,96,99,100] or from virus
infections 20–50 years prior to carcinogenesis [26]. Because
of these long preneoplastic histories such mutations are also
termed “archaeological” mutations [95,96].
In sum, our data indicate that newly formed carcinoma-
specific karyotypes generate and maintain carcinomas, in-
dependent of latent viral sequences or mutations of tumor
suppressor genes. Based on our findings it is expected that
a vaccine against human papilloma viruses will have no ef-
fect on the occurrence of cervical carcinomas.
2) Karyotypic mechanism of carcinomagenesis
In searching for alternatives of the putative viral and
mutational cervical carcinogens we found in theTable 3 Carcinoma-specific chromosome recombination
indices







SW-756 C1 and C2 15 and 25
HeLa R and S 10 and 20
MS-751 45literature a long-known cervical carcinoma-specific car-
cinogen, namely cigarette smoke. Surprisingly, in view of
the current viral and mutational theories, smoking was
already known in the 1970s to induce cervical carcin-
omas [27,80-83]. In 1983 a study of the Centers for Dis-
ease Control even proved that “12 or more pack-years
smoked” increase cervical carcinoma rates 12.4-fold
compared to non-smokers [79]. The steady decline of
cervical cancer in parallel with declining smoking rates
in the US supports this theory [38]. Other studies have in-
dependently shown that smoking induces preneoplastic an-
euploidy in proportion to the dose of cigarettes smoked
[101-105]. In addition ionizing radiation has been found to
induce cervical carcinomas too [106]. Thus, the induction
of aneuploidy by cigarette smoke or other carcinogens sup-
ports the karyotypic mechanism of carcinomagenesis pro-
posed here, and explains its characteristic time-dependence
owing to the inevitably slow karyotype mutation-selection
scheme outlined by the speciation theory (Background,
Figure 1).
The “early” preneoplastic or even neoplastic karyotypic al-
terations of cervical biopsies described by several investiga-
tors lend unexpected support to the karyotypic mechanism
of carcinomagenesis proposed by our theory [5,17,21,33,66,
70,107,108] (see also previous section). These investigators
may have used the proposition “early” for karyotypic alte-
rations, because they expected early carcinoma causing muta-
tions instead.
The speciation theory thus presents a coherent mecha-
nism of cervical carcinomagenesis in which carcinogens ini-
tiate carcinogenesis by inducing aneuploidy, and aneuploidy
then initiates automatic chain reactions of karyotypic evolu-
tions that eventually generate new carcinoma-specific
karyotypes.
Conclusions
Since conventional DNA cytometry has a blind spot for
near-diploid carcinomas and cancers, we propose that the
karyotype analyses performed here could provide new, ab-
solute distinctions between normal diploid but hyperplastic
cervical tissues, hyperplasias with random aneuploidies and
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tents and low Pap-grades, such as C-4II and C-33A
(Figures 6 and 7).
Moreover, our results promise new distinctions in grad-
ing malignancy of biopsies with high near-triploid DNA
contents - based on the number of clonal versus non-
clonal chromosomes, and on the corresponding chromo-
some recombination indices described here (Table 3). This
speculation seems justified, because our results confirm the
rule (Background): The more “abnormal” the “DNA con-
tent” – the higher is the flexibility and thus the malignancy
of the carcinoma [1,3-6,10,17,59,65,67].
Thus the karyotypic mechanism of carcinomagenesis
described here offers new, testable karyotypic markers to
distinguish between benign diploid biopsies, as yet benign
biopsies with non-clonal preneoplastic aneuploidies [58],
and malignant carcinomas with clonal near-diploid and
near-triploid karyotypes like those shown in Figures 6, 7, 8,
9, 10, 11, 12, 13 and 14.
In view of this we think our results provide the basis for a
new and improved approach to the diagnosis, treatment and
prevention of cervical carcinomas along the lines of the ori-
ginal discoveries of Papanicolaou et al. [1].
Methods
Cells and cell culture
The papilloma virus-free human cervical carcinoma cell
lines C-33A and HT-3, and the viral DNA-positive lines
C-4II and CaSki were obtained from American Type Cul-
ture Collection (Manassas, VA). The cervical carcinoma
lines SiHa, ME-180, MS-751, SW-756 and a second strain
of CaSki were kind gifts of Pulivarthi Rao (Laboratory of
Molecular Cytogenetics, Texas Children's Cancer Center,
Baylor College of Medicine, Houston, Texas). The HeLa
line was a kind gift of Ann Fischer (Cell culture facility at
UC Berkeley, Barker Hall). Cells were propagated in cell
culture medium RPMI 1640 (Sigma Co) supplemented
with 5% or 10% fetal calf serum, 1% Anti-Anti (GibCo
company) and 1% Nystatin (Sigma company).
Karyotype analysis of cervical carcinoma cells
One to two days before karyotyping, cells were seeded at
about 50% confluence in 3 ml medium containing 5% fetal
calf serum in a 5-cm culture dish. After reaching ~75% con-
fluence, 200 ng colcemid in 20 μl solution (KaryoMax, Gibco
Invitrogen company) was added to 3 ml medium. The cul-
ture was then incubated at 37°C for 4–8 hrs. Subsequently
cells were dissociated with trypsin, washed once in 3 ml of
physiological saline, and then incubated in 0.075 molar KCl
at 37°C for 15 min. After cooling the solution in ice-water,
0.1 volume of freshly mixed glacial acetic acid-methanol (1:3,
vol. per vol.) was added and the mixture was centrifuged at
800 g for 6 minutes at room temperature. The cell pellet was
then suspended drop-wise in ice-cold acetic acid-methanol(1:3) solution and incubated at room temperature for 15
min. This cell suspension was then pelleted by centrifuga-
tion as described above, resuspended in an appropriate
small volume and either transferred onto a microscope
slide with a micropipette tip to give a suitable density of
metaphases for microscopic analysis or stored at -20C.
Slides with suitable metaphase chromosomes were hybrid-
ized with chromosome-specific color-coded DNA probes
(MetaSystems, Newton, MA 02458), as described by the
manufacturer and by us previously [45,83], to generate the
chromosome-specific colors shown above in Figure 5.Note added in proof
Stepanenko and Kavsan have recently published an inde-
pendent speciation theory of cancer similar to the one
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